FindTrial
Sign In

Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220205
Enrollment
Unknown
Registered
2006-02-07
Start date
2006-02-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: PS=0-1, Age < 75 yrs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026